ID
43834
Description
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Demography Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast
Link
https://clinicaltrials.gov/ct2/show/NCT00078572
Keywords
Versions (2)
- 5/18/17 5/18/17 -
- 9/20/21 9/20/21 -
Uploaded on
September 20, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
Description
Demography for Females
Alias
- UMLS CUI-1
- C0011298
- UMLS CUI-2
- C0086287
Description
Childbearing potential
Data type
text
Alias
- UMLS CUI [1]
- C3831118
Description
contraception
Data type
integer
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Description
Contraception
Data type
text
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Description
Pregnancy test result
Data type
text
Alias
- UMLS CUI [1]
- C0032976
Similar models
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
C0086287 (UMLS CUI-2)
C0420837 (UMLS CUI [1,2])
C0420837 (UMLS CUI [1,2])